Hypercoagulable states and cerebrovascular disease

Kathryn F Kirchoff-Torres MD (Dr. Kirchoff-Torres of Albert Einstein College of Medicine has no relevant financial relationships to disclose.)
Steven R Levine MD, editor. (Dr. Levine of the SUNY Health Science Center at Brooklyn has received honorariums from Genentech for service on a scientific advisory committee and a research grant from Genentech as a principal investigator.)
Originally released March 18, 1997; last updated November 22, 2016; expires November 22, 2019

This article includes discussion of hypercoagulable states and cerebrovascular disease, hypercoagulability, thrombophilia, and prothrombotic. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Overview

In this update, the author discusses advances in the epidemiology, diagnosis, treatment, and prognosis of patients with ischemic stroke and cerebral venous thrombosis associated with genetic and acquired thrombophilia.

Key points

 

• Genetic and acquired hypercoagulable states, such as factor V Leiden deficiency and antiphospholipid syndrome, are associated with cerebrovascular events, including cerebral venous thrombosis and ischemic stroke.

 

• Understanding the pathophysiology of the hypercoagulable state is essential to understand the associated stroke syndromes and appropriate treatments.

 

• Study of the epidemiology, pathophysiology, and treatment of many recently described hypercoagulable states is an active and important area of research in neurology.

Historical note and terminology

Rudolf Virchow proposed in 1862 that the pathophysiology of thrombosis involved a triad of interrelated factors: damage to blood vessel endothelium, stasis of blood flow, and disorders in blood coagulability.

Image: Virchow triad
Today, thrombophilia is broadly defined as both inherited and acquired conditions that predispose to venous or arterial thrombosis. The term "hypercoagulable state" is defined as a prothrombotic condition resulting from any specific disorders of blood coagulation. Although the clinical concept of hypercoagulability has been appreciated for decades, only since the 1980s has it been possible to identify an underlying disorder of coagulation in a subset of patients with thrombosis. These disorders may be hereditary or acquired. Activated protein C resistance due to factor V Leiden mutation, prothrombin 20210A gene mutation, protein C deficiency, protein S deficiency, and antithrombin III deficiency are the most frequently seen causes of a hereditary hypercoagulable state; antiphospholipid antibody syndrome is the most common acquired disorder.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.